华熙生物(688363)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688363 华熙生物

已收盘 04-10 15:00:01

{"stockData":{"symbol":"688363","market":"SH","secType":"STK","nameCN":"华熙生物","latestPrice":42.2,"timestamp":1775804401000,"preClose":42.03,"halted":0,"volume":1927797,"delay":0,"changeRate":0.004,"floatShares":482000000,"shares":482000000,"eps":0.1342,"marketStatus":"已收盘","change":0.17,"latestTime":"04-10 15:00:01","open":42.12,"high":42.65,"low":42.07,"amount":81664800,"amplitude":0.0138,"askPrice":42.22,"askSize":7,"bidPrice":42.2,"bidSize":271,"shortable":0,"etf":0,"ttmEps":0.1342,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":5,"adr":0,"adjPreClose":42.03,"symbolType":"stock_kcb","openAndCloseTimeList":[[1775784600000,1775791800000],[1775797200000,1775804400000]],"highLimit":46.23,"lowLimit":37.83,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":481678242,"isCdr":false,"pbRate":2.88,"roa":"--","peRate":314.456036,"roe":"3.63%","epsLYR":0.36,"committee":0.646512,"marketValue":20327000000,"turnoverRate":0.004,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-13。","afterMarket":{"amount":0,"volume":0,"close":42.2,"buyVolume":0,"sellVolume":0,"time":1775806437558,"indexStatus":"已收盘 04-10 15:30:00","preClose":42.03},"floatMarketCap":20327000000},"requestUrl":"/m/hq/s/688363","defaultTab":"news","newsList":[{"id":"2621777168","title":"破发股华熙生物跌5.81%创新低 2019年上市募23.69亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777168","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621777168?lang=zh_cn&edition=full","pubTime":"2026-03-23 17:29","pubTimestamp":1774258151,"startTime":"0","endTime":"0","summary":"中国经济网北京3月23日讯 华熙生物 今日收报40.50元，跌幅5.81%。华熙生物今日盘中股价最低至40.36元，创历史新低。该股目前处于破发状态。　　2019年11月6日，华熙生物在上交所科创板上市，发行价格为47.79元/股，募集资金总额为23.69亿元，扣除发行费用后，募集资金净额为22.49亿元。华熙生物的发行费用合计为 11,964.01 万元，其中保荐及承销费等为9,666.00万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260323/32090564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688363","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619344024","title":"玻尿酸王座崩塌：华熙生物从1400亿到217亿的生死突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2619344024","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619344024?lang=zh_cn&edition=full","pubTime":"2026-03-16 14:40","pubTimestamp":1773643239,"startTime":"0","endTime":"0","summary":"文｜《思维深潜研究组》2026 年 2 月末，华熙生物 2025 年业绩快报落地：全年营收 42.17 亿元，同比下滑 21.49%；归母净利润 2.91 亿元，同比大增 67.03%。流量驱动、多品牌分散、渠道价格混乱，叠加行业退潮，华熙从神坛跌落，当前市值约 217 亿元。玻尿酸基本盘之外，胶原蛋白、聚乳酸、合成生物学、再生材料决定未来市值。华熙生物的起落、三强的鏖战、C 端的突围、全球化的起步，共同构成中国制造向中国品牌升级的缩影。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1773563588661892485","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","BK0229","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617663216","title":"华熙生物公布国际专利申请：“油性组合物及其用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663216","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617663216?lang=zh_cn&edition=full","pubTime":"2026-03-08 05:16","pubTimestamp":1772918181,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示华熙生物（688363）公布了一项国际专利申请，专利名为“油性组合物及其用途”，专利申请号为PCT/CN2025/116285，国际公布日为2026年3月5日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来华熙生物已公布的国际专利申请2个，较去年同期增加了100%。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.31亿元，同比增15.25%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616333262","title":"华熙生物2025年营收42亿：同比降21% 净利2.9亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2616333262","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616333262?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:55","pubTimestamp":1772456102,"startTime":"0","endTime":"0","summary":"华熙生物（证券代码：688363）日前发布2025年业绩快报，业绩快报显示，华熙生物2025年营收42.17亿，较上年同期的53.71亿元降21.49%。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260302/6390808169942304828177013.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260302/6390808169942304828177013.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n32767/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616488843","title":"每周股票复盘：华熙生物（688363）净利增67.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616488843","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616488843?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:13","pubTimestamp":1772302390,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，华熙生物报收于47.36元，较上周的47.25元上涨0.23%。本周，华熙生物2月25日盘中最高价报48.82元。华熙生物当前最新总市值228.12亿元，在医疗美容板块市值排名2/3，在两市A股市值排名977/5189。本周关注点业绩披露要点：华熙生物2025年归属净利润同比增长67.03%。公司公告汇总华熙生物发布2025年度业绩快报，营业总收入为42.17亿元，同比下降21.49%；归属于母公司所有者的净利润为2.91亿元，同比增长67.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688363","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614897643","title":"营收跌21%、净利却大增近七成！华熙生物“断臂求生”见效","url":"https://stock-news.laohu8.com/highlight/detail?id=2614897643","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614897643?lang=zh_cn&edition=full","pubTime":"2026-02-28 13:30","pubTimestamp":1772256600,"startTime":"0","endTime":"0","summary":"　　2月27日晚间，华熙生物发布2025年度业绩快报称，报告期内，公司实现营业收入42.17亿元，与上年同期的53.71亿元相比减少了21.49%；实现归属于母公司所有者的净利润2.91亿元，比上年同期增加67.03%；实现归属于母公司所有者的扣除非经常性损益的净利润1.88亿元，比上年同期增加75.28%。报告期末总资产86.55亿元，较期初下降0.02%；归属于母公司的所有者权益70.84亿元，较期初增加 4.02%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-28/doc-inhpiwhn3009086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614835062","title":"华熙生物发布2025年度业绩快报，盈利2.911亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614835062","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614835062?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:24","pubTimestamp":1772184270,"startTime":"0","endTime":"0","summary":"证券之星消息，华熙生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润盈利2.911亿元，同比增长67.03%。华熙生物主营业务：华熙生物是全球领先的、以透明质酸微生物发酵生产技术为核心的高新技术企业,透明质酸产业化规模位居国际前列。该股最近90天内共有7家机构给出评级，买入评级4家，增持评级2家，中性评级1家；过去90天内机构目标均价为54.28。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700029045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","BK0239","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614011355","title":"华熙生物赵燕：支持科技抗衰，但坚决反对改头换面的大手术医美","url":"https://stock-news.laohu8.com/highlight/detail?id=2614011355","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614011355?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:42","pubTimestamp":1772098920,"startTime":"0","endTime":"0","summary":"　　在对话中，华熙生物董事长赵燕谈及“自然美和医美”时表示，只要是自己认可的都是美。但是，她明确表示反对“改头换面的大手术医美”。　　赵燕谈到，用现代的一些科技手段、科技产品，能对自己的衰老做一些干预，让自己更年轻，从而更自信，心态也能回到年轻的状态，这个还是非常认的。　　赵燕表示，不排除市场上有一些医美机构过度放大了焦虑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-02-26/doc-inhpcusk4403266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0229","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614019156","title":"年轻人活得比较自我？华熙生物赵燕：这没做错","url":"https://stock-news.laohu8.com/highlight/detail?id=2614019156","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614019156?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:27","pubTimestamp":1772098020,"startTime":"0","endTime":"0","summary":"　　在对话中，华熙生物董事长赵燕表示，和年轻人在一起的时候，除了好奇、勇气和坚韧，还需要了解到他们在关注什么，认真去分析底层原因。　　赵燕强调，尤其是企业做研发，一定要观察现在有哪些消费者的需求是未被满足的，而且一定要能够打动他的情绪连接点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-02-26/doc-inhpcusf0504873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688363","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614150570","title":"华熙生物赵燕：医美让人重拾自信，优雅变老","url":"https://stock-news.laohu8.com/highlight/detail?id=2614150570","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614150570?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:08","pubTimestamp":1772096880,"startTime":"0","endTime":"0","summary":"　　赵燕表示，大家都认为衰老是一个自然过程，但是在生命科学领域来说，衰老是能够被主动干预和控制的过程。华熙生物的使命，是让每个生命都是鲜活的，所以要提高生命质量，让人活得长。“医美说到底，是让人重拾自信，尤其对于女性，能够很优雅地变老，更多的是一个心理上的慰藉。”","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-02-26/doc-inhpcusf0489597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688363","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608885712","title":"股市必读：华熙生物（688363）预计2025年全年归属净利润盈利2.7亿元至3.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608885712","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608885712?lang=zh_cn&edition=full","pubTime":"2026-02-02 01:50","pubTimestamp":1769968223,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，华熙生物报收于44.83元，下跌3.2%，换手率0.96%，成交量4.64万手，成交额2.1亿元。来自公司公告汇总：华熙生物预计2025年扣非后净利润同比增长55.68%至102.29%，业绩增长主要源于组织架构优化与运营成本下降。业绩披露要点业绩预告华熙生物发布业绩预告，预计2025年全年归属净利润盈利2.7亿元至3.2亿元；扣非后净利润盈利1.67亿元至2.17亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200000859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607377041","title":"华熙生物（688363）披露2025年年度业绩预增公告，1月30日股价下跌3.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607377041","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607377041?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:27","pubTimestamp":1769783240,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，华熙生物报收于44.83元，较前一交易日下跌3.2%，最新总市值为215.94亿元。该股当日开盘46.61元，最高46.61元，最低44.83元，成交额达2.1亿元，换手率为0.96%。近日，华熙生物科技股份有限公司发布2025年年度业绩预增公告。公告显示，公司预计2025年年度实现归属于母公司所有者的净利润27,000.00万元到32,000.00万元，同比增加54.93%到83.63%；扣除非经常性损益的净利润16,700.00万元到21,700.00万元，同比增加55.68%到102.29%。上年同期净利润基数较小，进一步放大增幅。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688363","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607709867","title":"可以让人活到120岁！华熙生物董事长回应争议言论","url":"https://stock-news.laohu8.com/highlight/detail?id=2607709867","media":"快科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607709867?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:39","pubTimestamp":1769737196,"startTime":"0","endTime":"0","summary":"快科技1月30日消息，此前，华熙生物董事长、总裁赵燕曾公开表示：“让人能够健康，能蹦能跳，能吃能睡的活到超过120岁”，该言论也引发网络热议。昨晚在“企业家之夜”活动上，她再次回应此事。在她看来，未来10年由于科技的发展，重大疾病将要被解决掉。官网显示，华熙生物成立于2000年，公司率先实现抗衰核心物质透明质酸的生物制造，市场份额常年全球第一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8qKaGjQKJlf","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK0239","688363","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605281761","title":"华熙生物公布国际专利申请：“一种Cas蛋白及其基因编辑系统和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2605281761","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605281761?lang=zh_cn&edition=full","pubTime":"2026-01-24 08:50","pubTimestamp":1769215844,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示华熙生物（688363）公布了一项国际专利申请，专利名为“一种Cas蛋白及其基因编辑系统和应用”，专利申请号为PCT/CN2025/107574，国际公布日为2026年1月15日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来华熙生物已公布的国际专利申请1个，与去年同期持平。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.31亿元，同比增15.25%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012400011761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0229","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603964435","title":"1月16日华熙生物发布公告，股东减持478.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603964435","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603964435?lang=zh_cn&edition=full","pubTime":"2026-01-16 18:01","pubTimestamp":1768557692,"startTime":"0","endTime":"0","summary":"证券之星消息，1月16日华熙生物发布公告《华熙生物:华熙生物股东减持股份结果公告》，其股东国寿成达(上海)健康产业股权投资中心(有限合伙)于2026年1月8日至2026年1月15日间合计减持478.1万股，占公司目前总股本的0.9926%，变动期间该股股价上涨6.19%，截止1月15日收盘报47.37元。股东增减持详情见下表：根据华熙生物2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600029910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688363","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603646498","title":"股市必读：1月14日华熙生物现4笔大宗交易 机构净买入200.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603646498","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603646498?lang=zh_cn&edition=full","pubTime":"2026-01-15 02:17","pubTimestamp":1768414629,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，华熙生物报收于47.45元，上涨0.23%，换手率1.79%，成交量8.61万手，成交额4.12亿元。当日关注点来自交易信息汇总：1月14日主力资金净流出1004.52万元，散户资金净流入583.7万元。大宗交易1月14日华熙生物现4笔大宗交易，机构净买入200.33万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500001311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688363","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603502048","title":"1月13日华熙生物现17笔大宗交易 机构净买入2217.39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603502048","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603502048?lang=zh_cn&edition=full","pubTime":"2026-01-13 17:47","pubTimestamp":1768297666,"startTime":"0","endTime":"0","summary":"证券之星消息，1月13日华熙生物发生大宗交易，交易数据如下：近三个月该股共发生46笔大宗交易，合计成交3.37万手，折价成交46笔。该股近期无解禁股上市。截至2026年1月13日收盘，华熙生物报收于47.34元，上涨2.25%，换手率2.4%，成交量11.58万手，成交额5.46亿元。该股近半年内有股东持股变动，合计净减持485.26万股，股东增减持明细如下表：该股最近90天内共有10家机构给出评级，买入评级6家，增持评级4家；过去90天内机构目标均价为55.56。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300030407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602140535","title":"每周股票复盘：华熙生物（688363）股东减持485万股持股比降至5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602140535","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602140535?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:55","pubTimestamp":1768071309,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，华熙生物报收于46.23元，较上周的43.68元上涨5.84%。来自股本股东变化：股东国寿成达在2025年11月27日至2026年1月7日期间合计减持428.08万股，占总股本0.8887%。公司公告汇总华熙生物科技股份有限公司发布关于持股5%以上股东权益变动触及5%刻度的提示性公告。减持后，国寿成达持有公司股份24,083,913股，占总股本约5.00%。2025年11月26日至2026年1月7日，累计减持4,852,591股，减持比例1.0074%。本次权益变动后，持股数量为24,083,913股，持股比例由6.0074%降至5.0000%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0229","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601636496","title":"1月8日华熙生物发布公告，股东减持428.08万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601636496","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601636496?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:01","pubTimestamp":1767877261,"startTime":"0","endTime":"0","summary":"证券之星消息，1月8日华熙生物发布公告《华熙生物:华熙生物关于持股5%以上股东权益变动触及5%刻度的提示性公告》，其股东国寿成达(上海)健康产业股权投资中心(有限合伙)于2025年11月27日至2026年1月7日间合计减持428.08万股，占公司目前总股本的0.8887%，变动期间该股股价下跌7.64%，截止1月7日收盘报44.61元。股东增减持详情见下表：根据华熙生物2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800037292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601281706","title":"股市必读：1月6日华熙生物现29笔大宗交易 机构净买入3352.12万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601281706","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601281706?lang=zh_cn&edition=full","pubTime":"2026-01-07 03:25","pubTimestamp":1767727513,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，华熙生物报收于44.91元，上涨0.34%，换手率1.07%，成交量5.16万手，成交额2.31亿元。来自交易信息汇总：1月6日华熙生物发生29笔大宗交易，机构净买入3352.12万元。交易信息汇总资金流向1月6日主力资金净流入397.55万元；游资资金净流入359.82万元；散户资金净流出757.38万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700001511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688363","BK0229"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775838671948,"stockEarnings":[{"period":"1week","weight":0.0369},{"period":"1month","weight":-0.068},{"period":"3month","weight":-0.0872},{"period":"6month","weight":-0.2435},{"period":"1year","weight":-0.1387},{"period":"ytd","weight":-0.0339}],"compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":-0.0356},{"period":"3month","weight":-0.0326},{"period":"6month","weight":0.0229},{"period":"1year","weight":0.2366},{"period":"ytd","weight":0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华熙生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30077人(较上一季度减少0.62%)","perCapita":"16014股","listingDate":"2019-11-06","address":"山东省济南市历下区高新技术开发区天辰大街678号","registeredCapital":"48167万元","survey":"　　华熙生物科技股份有限公司的主营业务是研发、生产和销售透明质酸等生物活性物质原料产品及生物医用材料终端产品。公司的主要产品是透明质酸、γ-氨基丁酸、聚谷氨酸钠、依克多因、麦角硫因、蛹虫草发酵滤液、纳豆提取液、糙米发酵滤液、微美态系列、微真、重组Ⅲ型人源化胶原蛋白、PDRN、脂肽、PQQ等。公司凭借技术领先性和产业引领带动作用，获得国家制造业单项冠军示范企业、国家知识产权优势企业、山东省科技进步一等奖、山东省省长质量奖、中国商业联合会特等奖等国家级、省级荣誉。2024年，公司科技创新能力持续获得认可，合成生物学国际研发中心的企业主体先后被认定为中关村高新技术企业、国家级科技型中小企业、国家高新技术企业等，北京市博士后科研工作站正式揭牌。","listedPrice":47.79},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华熙生物(688363)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华熙生物(688363)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华熙生物,688363,华熙生物股票,华熙生物股票老虎,华熙生物股票老虎国际,华熙生物行情,华熙生物股票行情,华熙生物股价,华熙生物股市,华熙生物股票价格,华熙生物股票交易,华熙生物股票购买,华熙生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华熙生物(688363)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华熙生物(688363)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}